salicylic acid has been researched along with Lichen Planus in 95 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Lichen Planus: An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When lichen planus involves the scalp, it is known as lichen planopilaris, and when it involves the eye, it is known as ocular lichen planus; both are rare." | 4.98 | Pediatric ocular lichen planus and lichen planopilaris: One new case and a review of the literature. ( Bevans, SL; Fowler, PG; Pavlidakey, PG; Sami, N; Stoll, M; Theos, AJ, 2018) |
| "The most important hair diseases are divided in non- cicatricial and cicatricial ones." | 2.72 | Common causes of hair loss - clinical manifestations, trichoscopy and therapy. ( Alessandrini, A; Bruni, F; Piraccini, BM; Starace, M, 2021) |
| "Analyzing other scarring diseases (lichen planopilaris, fibrotic kidney disease and scleroderma) may help to clarify the mechanism of scarring in CCCA." | 2.66 | A proposed mechanism for central centrifugal cicatricial alopecia. ( Alexander, T; Beamer, V; McMichael, A; Subash, J, 2020) |
| "The result is a permanent scarring hair loss accentuated at the front hairline with backward movement towards the neck mostly accompanied by a typical loss of the eyebrows." | 2.58 | [Postmenopausal lichen planopilaris also known as fibrosing frontotemporal alopecia Kossard : An evidence-oriented practical guide to treatment from the University of the Saarland, Hair Research Center of the Dr. Rolf M. Schwiete Foundation]. ( Christmann, R; Lehr, CM; Loretz, B; Mawlood, D; Müller, C; Reichrath, J; Schäfer, U; Schilling, L; Thomas, C; Vogt, T, 2018) |
| "Folliculitis keloidalis is a cicatricial alopecia with a mixed inflammatory infiltrate." | 2.52 | Primary scarring alopecias. ( Ioannides, D; Rigopoulos, D; Stamatios, G, 2015) |
| "Sarcoidosis is an idiopathic multisystem inflammatory disease that can affect virtually any part of the body." | 1.91 | Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series. ( Hosler, GA; Khalid, I; Ogwumike, E; Sode, T, 2023) |
| "Mucosal lichen planus was found in four patients (21." | 1.62 | Lichen planopilaris in men: a retrospective clinicopathologic study of 19 patients. ( Cantwell, HM; Imhof, RL; Proffer, SL; Tolkachjov, SN; Torgerson, RR; Wieland, CN, 2021) |
| "Six patients had progression of their hair loss in spite of treatment." | 1.62 | Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study. ( Bhoyrul, B; Jerjen, R; Pinczewski, J; Sinclair, R, 2021) |
| "Alopecia is one of these." | 1.56 | Eosinophilic folliculitis of the scalp associated with PD-1/PDL1 inhibitors. ( Carlesimo, M; Caro, G; De Vincentiis, L; Federico, A; Fortuna, MC; Magri, F; Rossi, A; Soda, G, 2020) |
| "One patient had hair loss of the upper cutaneous lip." | 1.46 | Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases. ( Camilleri, MJ; Chaudhry, HM; Tolkachjov, SN; Torgerson, RR, 2017) |
| "A new subtype of LPP mimicking androgenetic alopecia (AGA) may be misdiagnosed." | 1.43 | A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia. ( Abbasi, A; Abbasi, S; Kamyab-Hesari, K; Mollaee, F; Rabbani, R, 2016) |
| "Imiquimod 5% cream is an immune-response-modifying drug with antiviral and anti-tumour activity." | 1.42 | Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome. ( Argenziano, G; Drummond, A; Lallas, A; Longo, C; Moscarella, E; Piana, S; Pichler, J; Zalaudek, I, 2015) |
| "FFA is an increasingly common form of scarring hair loss, but the origin remains unknown." | 1.39 | Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. ( Bazakas, A; Ladizinski, B; Olsen, EA; Selim, MA, 2013) |
| "Lichen planopilaris (LPP) and pseudopelade of Brocq (PPB) are two scarring alopecia diagnoses that exhibit similar clinical features." | 1.36 | Lichen planopilaris and pseudopelade of Brocq involve distinct disease associated gene expression patterns by microarray. ( Bell, RH; Haegert, A; Isaac-Renton, M; Lo, BK; Martinka, M; McElwee, KJ; Ross, EK; Shapiro, J; Yu, M, 2010) |
| "However, eyebrow loss and hair loss in other body sites may also occur; this has been documented clinically, but rarely histopathologically." | 1.36 | Expanding the spectrum of frontal fibrosing alopecia: a unifying concept. ( Bashir, SJ; Chew, AL; Fenton, DA; Stefanato, CM; Wain, EM, 2010) |
| "All had frontotemporal recession with scarring." | 1.35 | Frontal fibrosing alopecia: clinical presentations and prognosis. ( Messenger, AG; Tan, KT, 2009) |
| "In 1885 Brocq described a type of scarring alopecia he called pseudopelade (PPB), whose character as a separate disease entity has been denied in recent decades." | 1.28 | [The Brocq pseudopelade--a disease picture or disease entity]. ( Bergner, T; Braun-Falco, O; Heilgemeir, GP, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (12.63) | 18.7374 |
| 1990's | 7 (7.37) | 18.2507 |
| 2000's | 6 (6.32) | 29.6817 |
| 2010's | 34 (35.79) | 24.3611 |
| 2020's | 36 (37.89) | 2.80 |
| Authors | Studies |
|---|---|
| SHATIN, H | 1 |
| CANIZARES, O | 1 |
| WORTHINGTON, EL | 1 |
| Frew, D | 1 |
| Oaxaca, G | 1 |
| Habermehl, G | 1 |
| Unwala, R | 1 |
| Bergfeld, W | 6 |
| Shahidi-Dadras, M | 1 |
| Asadi Kani, Z | 1 |
| Dadkhahfar, S | 1 |
| Zartab, H | 1 |
| Rakhshan, A | 1 |
| Arasu, A | 1 |
| Meah, N | 2 |
| Marzola, M | 1 |
| Sinclair, R | 4 |
| Blume-Peytavi, U | 2 |
| Hillmann, K | 1 |
| Constantinou, A | 1 |
| Vogt, A | 2 |
| Pathoulas, JT | 4 |
| Flanagan, KE | 4 |
| Su, MY | 1 |
| Elmariah, SB | 1 |
| Zhan, Y | 1 |
| Walker, CJ | 4 |
| Burns, LJ | 1 |
| Manatis-Lornell, A | 1 |
| Penzi, L | 1 |
| Miller, DD | 1 |
| Hordinsky, MK | 7 |
| Senna, MM | 4 |
| Kępińska, K | 1 |
| Jałowska, M | 1 |
| Bowszyc-Dmochowska, M | 1 |
| Saad, S | 1 |
| Cavelier-Balloy, B | 1 |
| Smadja, J | 1 |
| Assouly, P | 1 |
| Reygagne, P | 2 |
| Miteva, M | 2 |
| Nadji, M | 1 |
| Billero, V | 1 |
| LaSenna, C | 1 |
| Nattkemper, L | 1 |
| Romanelli, P | 1 |
| Collins, MS | 3 |
| Ali, S | 3 |
| Pupo Wiss, IM | 3 |
| Cotsarelis, G | 4 |
| Milbar, H | 3 |
| Huang, K | 3 |
| Mostaghimi, A | 3 |
| Scott, D | 3 |
| Han, JJ | 3 |
| Lee, KJ | 3 |
| Farah, RS | 3 |
| Bellefeuille, G | 3 |
| Raymond, O | 3 |
| Ranasinghe, G | 3 |
| Shapiro, J | 6 |
| Lo Sicco, KI | 3 |
| Gutierrez, D | 3 |
| Ko, J | 3 |
| Mirmirani, P | 5 |
| Mesinkovska, N | 3 |
| Yale, KL | 3 |
| Goldberg, LJ | 3 |
| Tosti, A | 6 |
| Gwillim, EC | 3 |
| Goh, C | 3 |
| Karim, N | 1 |
| Durbin-Johnson, BP | 1 |
| Rocke, DM | 1 |
| Salemi, M | 1 |
| Phinney, BS | 1 |
| Rice, RH | 1 |
| Sode, T | 1 |
| Ogwumike, E | 1 |
| Hosler, GA | 1 |
| Khalid, I | 1 |
| Orlando, G | 1 |
| Salmaso, R | 1 |
| Piaserico, S | 1 |
| Ramot, Y | 1 |
| Bertolini, M | 1 |
| Boboljova, M | 1 |
| Uchida, Y | 1 |
| Paus, R | 3 |
| Harries, M | 3 |
| Hardman, J | 1 |
| Chaudhry, I | 1 |
| Poblet, E | 3 |
| Griggs, J | 1 |
| Trüeb, RM | 2 |
| Gavazzoni Dias, MFR | 1 |
| Hordinsky, M | 2 |
| Lee, JA | 1 |
| Levy, DA | 1 |
| Patel, KG | 1 |
| Brennan, E | 1 |
| Oyer, SL | 1 |
| Del Duca, E | 2 |
| Ruano Ruiz, J | 2 |
| Pavel, AB | 2 |
| Sanyal, RD | 1 |
| Song, T | 1 |
| Gay-Mimbrera, J | 2 |
| Zhang, N | 2 |
| Estrada, YD | 2 |
| Peng, X | 1 |
| Renert-Yuval, Y | 1 |
| Phelps, RG | 2 |
| Krueger, JG | 2 |
| Guttman-Yassky, E | 2 |
| Rossi, A | 1 |
| Magri, F | 1 |
| Caro, G | 1 |
| Federico, A | 1 |
| Fortuna, MC | 1 |
| Soda, G | 1 |
| De Vincentiis, L | 1 |
| Carlesimo, M | 1 |
| Bosch-Amate, X | 1 |
| Riquelme-McLoughlin, C | 1 |
| Morgado-Carrasco, D | 1 |
| Rojano-Fritz, L | 1 |
| Iranzo-Fernández, P | 1 |
| Bhoyrul, B | 2 |
| Trindade de Carvalho, L | 1 |
| Wall, D | 1 |
| Kurzeja, M | 1 |
| Czuwara, J | 1 |
| Walecka, I | 1 |
| Olszewska, M | 1 |
| Rudnicka, L | 3 |
| Cantwell, HM | 1 |
| Wieland, CN | 1 |
| Proffer, SL | 1 |
| Imhof, RL | 1 |
| Torgerson, RR | 2 |
| Tolkachjov, SN | 2 |
| Mofarrah, R | 2 |
| Jahani Amiri, K | 1 |
| Ghasemi, M | 1 |
| Alessandrini, A | 1 |
| Bruni, F | 1 |
| Piraccini, BM | 2 |
| Starace, M | 1 |
| Porriño-Bustamante, ML | 1 |
| Fernández-Pugnaire, MA | 1 |
| Castellote-Caballero, L | 1 |
| Arias-Santiago, S | 1 |
| Dubin, C | 1 |
| Glickman, JW | 1 |
| Chennareddy, S | 1 |
| Han, J | 1 |
| Dahabreh, D | 1 |
| Kimmel, GW | 1 |
| Singer, G | 1 |
| Chowdhury, M | 1 |
| Zheng, AY | 1 |
| Angelov, M | 1 |
| Olsen, EA | 2 |
| Callender, V | 1 |
| Chasapi, V | 1 |
| Correia, O | 1 |
| Dhurat, R | 1 |
| Dlova, N | 1 |
| Doche, I | 3 |
| Enechukwu, N | 1 |
| Grimalt, R | 1 |
| Itami, S | 1 |
| Khobzei, K | 1 |
| Lee, WS | 1 |
| Malakar, S | 1 |
| Messenger, A | 1 |
| McMichael, A | 3 |
| Ovcharenko, Y | 1 |
| Papanikou, S | 1 |
| Pinto, GM | 1 |
| Pirmez, R | 1 |
| Roberts, J | 1 |
| Saceda-Corralo, D | 1 |
| Silyuk, T | 1 |
| Soares, RO | 1 |
| Souissi, A | 1 |
| Washenik, K | 1 |
| Zlotogorski, A | 1 |
| Canfield, D | 1 |
| Vano-Galvan, S | 1 |
| Altemir, A | 1 |
| Lobato-Berezo, A | 1 |
| Pujol, RM | 1 |
| Golińska, J | 1 |
| Sar-Pomian, M | 1 |
| Svigos, K | 1 |
| Yin, L | 1 |
| Fried, L | 1 |
| Lo Sicco, K | 1 |
| Bretas, TLB | 1 |
| Issa, MC | 1 |
| Vargas, TJ | 1 |
| Sousa, MAJ | 1 |
| Jerjen, R | 1 |
| Pinczewski, J | 1 |
| Chaudhry, HM | 1 |
| Camilleri, MJ | 1 |
| Liu, YS | 1 |
| Jee, SH | 1 |
| Chan, JL | 1 |
| Sundberg, JP | 1 |
| Lenzy, YM | 1 |
| McMichael, AJ | 1 |
| Christiano, AM | 2 |
| McGregor, T | 1 |
| Stenn, KS | 1 |
| Sivamani, RK | 1 |
| Pratt, CH | 1 |
| King, LE | 1 |
| Vogt, T | 1 |
| Thomas, C | 1 |
| Reichrath, J | 1 |
| Schilling, L | 1 |
| Mawlood, D | 1 |
| Christmann, R | 1 |
| Loretz, B | 1 |
| Schäfer, U | 1 |
| Lehr, CM | 1 |
| Müller, C | 1 |
| Dina, Y | 1 |
| Okoye, GA | 1 |
| Aguh, C | 1 |
| Subash, J | 1 |
| Alexander, T | 1 |
| Beamer, V | 1 |
| Batrani, M | 1 |
| Kubba, A | 1 |
| Kubba, R | 1 |
| Bevans, SL | 1 |
| Theos, AJ | 1 |
| Fowler, PG | 1 |
| Pavlidakey, PG | 1 |
| Stoll, M | 1 |
| Sami, N | 1 |
| Costa-Silva, M | 1 |
| Osorio, F | 1 |
| Pedrosa, A | 1 |
| Santos, P | 1 |
| Azevedo, F | 1 |
| Yang, CC | 1 |
| Khanna, T | 1 |
| Sallee, B | 1 |
| Bordone, LA | 1 |
| Romiti, R | 2 |
| Valente, NS | 2 |
| Wilcox, GL | 1 |
| Ericson, M | 1 |
| McAdams, BD | 1 |
| Kushner, CJ | 1 |
| Concha, JSS | 1 |
| Pearson, DR | 1 |
| Werth, VP | 1 |
| Teramura, K | 1 |
| Kato, T | 1 |
| Nishikawa, J | 1 |
| Nakanishi, T | 1 |
| Tanaka, T | 1 |
| Fujimoto, N | 1 |
| Garcia-Robledo, JE | 1 |
| Aragón, CC | 1 |
| Nieto-Aristizábal, I | 1 |
| Vásquez, S | 1 |
| Montoya, C | 1 |
| Tobón, GJ | 1 |
| Eftekhari, H | 1 |
| Azimi, SZ | 1 |
| Rafiei, R | 1 |
| Darjani, A | 1 |
| Alizadeh, N | 1 |
| Rafiei, E | 1 |
| Ghadarjani, R | 1 |
| Gharaei Nejad, K | 1 |
| László, FG | 1 |
| Delacerda, AB | 1 |
| Chandler, RG | 1 |
| Wells, MJ | 1 |
| Vindhya, PL | 1 |
| Drummond, A | 1 |
| Pichler, J | 1 |
| Argenziano, G | 1 |
| Zalaudek, I | 1 |
| Longo, C | 1 |
| Lallas, A | 1 |
| Piana, S | 1 |
| Moscarella, E | 1 |
| Chan, DV | 1 |
| Kartono, F | 1 |
| Ziegler, R | 1 |
| Abdulwahab, N | 1 |
| DiPaola, N | 1 |
| Flynn, J | 1 |
| Wong, HK | 1 |
| Wilk, M | 1 |
| Zelger, BG | 1 |
| Zelger, B | 1 |
| Yorulmaz, A | 1 |
| Artuz, F | 1 |
| Er, O | 1 |
| Guresci, S | 1 |
| Ekpo, FE | 1 |
| Cibull, TL | 1 |
| Kaminska, EC | 1 |
| Rigopoulos, D | 1 |
| Stamatios, G | 1 |
| Ioannides, D | 1 |
| Lanoue, J | 1 |
| Yanofsky, VR | 1 |
| Mercer, SE | 1 |
| Ardigò, M | 1 |
| Agozzino, M | 1 |
| Franceschini, C | 1 |
| Donadio, C | 1 |
| Abraham, LS | 1 |
| Barbieri, L | 1 |
| Sperduti, I | 1 |
| Berardesca, E | 1 |
| González, S | 1 |
| Jimenez, F | 2 |
| Yeo, L | 1 |
| Ormerod, AD | 1 |
| Abbasi, A | 1 |
| Kamyab-Hesari, K | 1 |
| Rabbani, R | 1 |
| Mollaee, F | 1 |
| Abbasi, S | 1 |
| Bomar, L | 1 |
| Tandon, YK | 1 |
| Somani, N | 1 |
| Cevasco, NC | 1 |
| Bergfeld, WF | 1 |
| Tan, KT | 1 |
| Messenger, AG | 1 |
| Yu, M | 1 |
| Bell, RH | 1 |
| Ross, EK | 1 |
| Lo, BK | 1 |
| Isaac-Renton, M | 1 |
| Martinka, M | 2 |
| Haegert, A | 1 |
| McElwee, KJ | 1 |
| Lin, MY | 1 |
| Chen, LJ | 1 |
| Ma, L | 1 |
| Wu, WY | 1 |
| Xiang, LH | 1 |
| Ghoreishi, M | 1 |
| Dutz, JP | 1 |
| Armenores, P | 1 |
| Shirato, K | 1 |
| Reid, C | 1 |
| Sidhu, S | 1 |
| Chew, AL | 1 |
| Bashir, SJ | 1 |
| Wain, EM | 1 |
| Fenton, DA | 1 |
| Stefanato, CM | 1 |
| Binesh, F | 1 |
| Parichehr, K | 1 |
| Ladizinski, B | 1 |
| Bazakas, A | 1 |
| Selim, MA | 1 |
| Stockmeier, M | 1 |
| Kunte, C | 1 |
| Sander, CA | 1 |
| Wolff, H | 1 |
| AYRES, S | 2 |
| SANNICANDRO, G | 1 |
| DEGOS, R | 1 |
| RABUT, R | 1 |
| LEFORT, P | 1 |
| BORDA, JM | 2 |
| FABRICIO, R | 1 |
| SAN MARTIN, M | 1 |
| MAZZINI, RH | 1 |
| ACUSSE RUIZ, D | 1 |
| Pascual, A | 1 |
| Piqué, E | 1 |
| Jordon, RE | 1 |
| Isaac, M | 1 |
| McNeely, MC | 1 |
| Bayerl, C | 1 |
| Moll, I | 1 |
| Silvers, DN | 1 |
| Katz, BE | 1 |
| Young, AW | 1 |
| Nayar, M | 1 |
| Schomberg, K | 1 |
| Dawber, RP | 1 |
| Millard, PR | 1 |
| Kossard, S | 1 |
| Lee, MS | 1 |
| Wilkinson, B | 1 |
| Torricelli, R | 1 |
| Smith, KJ | 1 |
| Crittenden, J | 1 |
| Skelton, H | 1 |
| Nagy, E | 1 |
| Szakály, I | 1 |
| Matta, M | 1 |
| Kibbi, AG | 1 |
| Khattar, J | 1 |
| Salman, SM | 1 |
| Zaynoun, ST | 1 |
| Braun-Falco, O | 1 |
| Bergner, T | 1 |
| Heilgemeir, GP | 1 |
| Ebner, H | 1 |
| Chenegin, VM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE[NCT04300296] | Phase 2 | 111 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model. (NCT04300296)
Timeframe: Baseline up to week 16
| Intervention | percentage of participants (Median) |
|---|---|
| AIN457 300 mg Q4W - TP 1 - CLP Cohort | 44.0 |
| Placebo - TP 1 - CLP Cohort | 58.2 |
| AIN457 300 mg Q4W - TP 1 - MLP Cohort | 37.5 |
| Placebo - TP 1 - MLP Cohort | 23.1 |
| AIN457 300 mg Q4W - TP 1 - LPP Cohort | 37.6 |
| Placebo - TP 1 - LPP Cohort | 30.9 |
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 0 score | Week 16 0 score | Week 16 1 score | Week 16 2 score | Week 16 3 score | Week 16 4 score | Week 16 5 score | Week 20 0 score | Week 20 1 score | Week 20 2 score | Week 20 3 score | Week 20 4 score | Week 20 5 score | Week 24 0 score | Week 24 1 score | Week 24 2 score | Week 24 3 score | Week 24 4 score | Week 24 5 score | Week 28 0 score | Week 28 1 score | Week 28 2 score | Week 28 3 score | Week 28 4 score | Week 28 5 score | Week 32 0 score | Week 32 1 score | Week 32 2 score | Week 32 3 score | Week 32 4 score | Week 32 5 score | |
| Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 0 | 0 | 0 | 3 | 3 | 4 | 0 | 0 | 0 | 3 | 2 | 3 | 2 | 0 | 0 | 2 | 2 | 4 | 2 | 0 | 0 | 2 | 3 | 3 | 2 | 0 | 1 | 0 | 4 | 2 | 2 |
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 0 Score | Baseline 1 score | Baseline 2 score | Baseline 3 score | Baseline 4 score | Baseline 5 score | Week 2 0 score | Week 2 1 score | Week 2 2 score | Week 2 3 score | Week 2 4 score | Week 2 5 score | Week 4 0 score | Week 4 1 score | Week 4 2 score | Week 4 3 score | Week 4 4 score | Week 4 5 score | Week 8 0 score | Week 8 1 score | Week 8 2 score | Week 8 3 score | Week 8 4 score | Week 8 5 score | Week 12 0 score | Week 12 1 score | Week 12 2 score | Week 12 3 score | Week 12 4 score | Week 12 5 score | Week 16 0 score | Week 16 1 score | Week 16 2 score | Week 16 3 score | Week 16 4 score | Week 16 5 score | |
| Placebo - TP 1 - CLP Cohort | 0 | 0 | 0 | 3 | 6 | 3 | 0 | 0 | 1 | 3 | 5 | 3 | 0 | 0 | 0 | 3 | 5 | 3 | 0 | 1 | 1 | 2 | 4 | 3 | 0 | 1 | 2 | 0 | 7 | 2 | 0 | 2 | 3 | 3 | 4 | 0 |
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 0 Score | Baseline 1 score | Baseline 2 score | Baseline 3 score | Baseline 4 score | Baseline 5 score | Week 2 0 score | Week 2 1 score | Week 2 2 score | Week 2 3 score | Week 2 4 score | Week 2 5 score | Week 4 0 score | Week 4 1 score | Week 4 2 score | Week 4 3 score | Week 4 4 score | Week 4 5 score | Week 8 0 score | Week 8 1 score | Week 8 2 score | Week 8 3 score | Week 8 4 score | Week 8 5 score | Week 12 0 score | Week 12 1 score | Week 12 2 score | Week 12 3 score | Week 12 4 score | Week 12 5 score | Week 16 0 score | Week 16 1 score | Week 16 2 score | Week 16 3 score | Week 16 4 score | Week 16 5 score | Week 20 0 score | Week 20 1 score | Week 20 2 score | Week 20 3 score | Week 20 4 score | Week 20 5 score | Week 24 0 score | Week 24 1 score | Week 24 2 score | Week 24 3 score | Week 24 4 score | Week 24 5 score | Week 28 0 score | Week 28 1 score | Week 28 2 score | Week 28 3 score | Week 28 4 score | Week 28 5 score | Week 32 0 score | Week 32 1 score | Week 32 2 score | Week 32 3 score | Week 32 4 score | Week 32 5 score | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 0 | 3 | 6 | 6 | 5 | 5 | 0 | 6 | 5 | 9 | 3 | 2 | 0 | 3 | 8 | 8 | 3 | 2 | 0 | 7 | 5 | 7 | 4 | 2 | 0 | 6 | 7 | 7 | 3 | 2 | 0 | 4 | 12 | 5 | 2 | 2 | 0 | 6 | 12 | 3 | 1 | 2 | 1 | 8 | 10 | 1 | 2 | 3 | 0 | 6 | 11 | 1 | 3 | 2 | 2 | 5 | 10 | 3 | 1 | 3 |
"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Baseline n=25,12,0 | Week 4 n=24,11,0 | Week 8 n=25,11,0 | Week 12 n=25,12,0 | Week 16 n=25,12,10 | |
| Placebo - TP 1 - CLP Cohort | 0 | 0 | 0 | 1 | 2 |
"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Week 16 n=25,12,10 | Week 20 n=24,0,10 | Week 24 n=25,0,10 | Week 28 n=23,0,10 | Week 32 n=25,0,9 | |
| Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 2 | 1 | 1 | 1 | 1 |
"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline n=25,12,0 | Week 4 n=24,11,0 | Week 8 n=25,11,0 | Week 12 n=25,12,0 | Week 16 n=25,12,10 | Week 20 n=24,0,10 | Week 24 n=25,0,10 | Week 28 n=23,0,10 | Week 32 n=25,0,9 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 0 | 2 | 2 | 3 | 3 | 3 | 4 | 3 | 2 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,13 | |
| Placebo - TP 1 - LPP Cohort | 0 | 1 | 1 | 2 | 1 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Week 16 n=24,13,13 | Week 20 n=24,0,13 | Week 24 n=23,0,13 | Week 28 n=24,0,13 | Week 32 n=24,0,11 | |
| Placebo to AIN457 300 mg Q2W TP 2 - LPP Cohort | 1 | 3 | 3 | 2 | 3 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,13 | Week 20 n=24,0,13 | Week 24 n=23,0,13 | Week 28 n=24,0,13 | Week 32 n=24,0,11 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 0 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 1 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,11 | |
| Placebo - TP 1 - MLP Cohort | 0 | 1 | 1 | 2 | 3 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Week 16 n=24,13,11 | Week 20 n=24,0,11 | Week 24 n=24,0,10 | Week 28 n=23,0,11 | Week 32 n=23,0,10 | |
| Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 2 | 2 | 3 | 2 | 2 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,11 | Week 20 n=24,0,11 | Week 24 n=24,0,10 | Week 28 n=23,0,11 | Week 32 n=23,0,10 | |
| AIN457 300 mg Q4W - TP 1 and TP 2- MLP Cohort | 0 | 2 | 4 | 4 | 5 | 7 | 7 | 3 | 4 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 IGA <=2 n=25,12,0 | Week 2 IGA improvement >=2 n=25,12,0 | Week 2 IGA 0/1 n=25,12,0 | Week 4 IGA <=2 n=24,11,0 | Week 4 IGA improvement. >=2 n=24,11,0 | Week 4 IGA 0/1 n=24,11,0 | Week 8 IGA <=2 n=25,11,0 | Week 8 IGA improvement. >=2 n=25,11,0 | Week 8 IGA 0/1 n=25,11,0 | Week 12 IGA <=2 n=25,12,0 | Week 12 IGA improvement. >=2 n=25,12,0 | Week 12 IGA 0/1 n=25,12,0 | Week16 IGA <=2 n=25,12,10 | Week 16 IGA improvement. >=2 n=25,12,10 | Week 16 IGA 0/1 n=25,12,10 | |
| Placebo - TP 1 - CLP Cohort | 1 | 0 | 0 | 2 | 0 | 0 | 3 | 1 | 1 | 4 | 2 | 1 | 7 | 3 | 2 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week16 IGA <=2 n=25,12,10 | Week 16 IGA improvement. >=2 n=25,12,10 | Week 16 IGA 0/1 n=25,12,10 | Week 20 IGA <=2 n=24,0,10 | Week 20 IGA improvement. >=2 n=24,0,10 | Week 20 IGA 0/1 n=24,0,10 | Week 24 IGA <=2 n=25,0,10 | Week 24 IGA improvement. >=2 n=25,0,10 | Week 24 IGA 0/1 n=25,0,10 | Week 28 IGA <=2 n=23,0,10 | Week 28 IGA improvement. >=2 n=23,0,10 | Week 28 IGA 0/1 n=23,0,10 | Week 32 IGA <=2 n=24,0,9 | Week 32 IGA improvement. >=2 n=24,0,9 | Week 32 IGA 0/1 n=24,0,9 | |
| Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 5 | 1 | 0 | 1 | 1 | 1 | 3 | 2 | 1 | 4 | 1 | 1 | 2 | 2 | 1 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 IGA <=2 n=25,12,0 | Week 2 IGA improvement >=2 n=25,12,0 | Week 2 IGA 0/1 n=25,12,0 | Week 4 IGA <=2 n=24,11,0 | Week 4 IGA improvement. >=2 n=24,11,0 | Week 4 IGA 0/1 n=24,11,0 | Week 8 IGA <=2 n=25,11,0 | Week 8 IGA improvement. >=2 n=25,11,0 | Week 8 IGA 0/1 n=25,11,0 | Week 12 IGA <=2 n=25,12,0 | Week 12 IGA improvement. >=2 n=25,12,0 | Week 12 IGA 0/1 n=25,12,0 | Week16 IGA <=2 n=25,12,10 | Week 16 IGA improvement. >=2 n=25,12,10 | Week 16 IGA 0/1 n=25,12,10 | Week 20 IGA <=2 n=24,0,10 | Week 20 IGA improvement. >=2 n=24,0,10 | Week 20 IGA 0/1 n=24,0,10 | Week 24 IGA <=2 n=25,0,10 | Week 24 IGA improvement. >=2 n=25,0,10 | Week 24 IGA 0/1 n=25,0,10 | Week 28 IGA <=2 n=23,0,10 | Week 28 IGA improvement. >=2 n=23,0,10 | Week 28 IGA 0/1 n=23,0,10 | Week 32 IGA <=2 n=24,0,9 | Week 32 IGA improvement. >=2 n=24,0,9 | Week 32 IGA 0/1 n=24,0,9 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 5 | 2 | 2 | 9 | 3 | 2 | 10 | 4 | 3 | 10 | 3 | 4 | 11 | 4 | 4 | 11 | 5 | 5 | 14 | 10 | 10 | 12 | 7 | 6 | 9 | 7 | 6 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 IGA <=2 n=24,13,0 | Week 2 IGA improvement >=2 n=24,13,0 | Week 2 IGA 0/1 n=24,13,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,13 | Week 16 IGA improvement. >=2 n=24,13,13 | Week 16 IGA 0/1 n=24,13,13 | |
| Placebo - TP 1 - LPP Cohort | 1 | 0 | 0 | 2 | 1 | 1 | 3 | 1 | 1 | 4 | 2 | 2 | 4 | 0 | 0 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week16 IGA <=2 n=24,13,13 | Week 16 IGA improvement. >=2 n=24,13,13 | Week 16 IGA 0/1 n=24,13,13 | Week 20 IGA <=2 n=24,0,13 | Week 20 IGA improvement. >=2 n=24,0,13 | Week 20 IGA 0/1 n=24,0,13 | Week 24 IGA <=2 n=23,0,13 | Week 24 IGA improvement. >=2 n=23,0,13 | Week 24 IGA 0/1 n=23,0,13 | Week 28 IGA <=2 n=24,0,13 | Week 28 IGA improvement. >=2 n=24,0,13 | Week 28 IGA 0/1 n=24,0,13 | Week 32 IGA <=2 n==24,0,11 | Week 32 IGA improvement. >=2 n==24,0,11 | Week 32 IGA 0/1 n==24,0,11 | |
| Placebo to AIN457 300 mg Q2W - TP 2- LPP Cohort | 4 | 0 | 0 | 6 | 1 | 0 | 8 | 3 | 2 | 9 | 4 | 3 | 7 | 5 | 4 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 IGA <=2 n=24,13,0 | Week 2 IGA improvement >=2 n=24,13,0 | Week 2 IGA 0/1 n=24,13,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,13 | Week 16 IGA improvement. >=2 n=24,13,13 | Week 16 IGA 0/1 n=24,13,13 | Week 20 IGA <=2 n=24,0,13 | Week 20 IGA improvement. >=2 n=24,0,13 | Week 20 IGA 0/1 n=24,0,13 | Week 24 IGA <=2 n=23,0,13 | Week 24 IGA improvement. >=2 n=23,0,13 | Week 24 IGA 0/1 n=23,0,13 | Week 28 IGA <=2 n=24,0,13 | Week 28 IGA improvement. >=2 n=24,0,13 | Week 28 IGA 0/1 n=24,0,13 | Week 32 IGA <=2 n==24,0,11 | Week 32 IGA improvement. >=2 n==24,0,11 | Week 32 IGA 0/1 n==24,0,11 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 4 | 1 | 1 | 9 | 2 | 2 | 8 | 3 | 3 | 8 | 3 | 2 | 9 | 3 | 2 | 10 | 6 | 4 | 10 | 7 | 6 | 10 | 6 | 5 | 11 | 5 | 4 |
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 IGA <=2 n=24,12,0 | Week 2 IGA improvement >=2 n=24,12,0 | Week 2 IGA 0/1 n=24,12,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,11 | Week 16 IGA improvement. >=2 n=24,13,11 | Week 16 IGA 0/1 n=24,13,11 | |
| Placebo - TP 1 - MLP Cohort | 3 | 1 | 1 | 2 | 1 | 1 | 3 | 2 | 1 | 4 | 4 | 2 | 3 | 3 | 2 |
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week16 IGA <=2 n=24,13,11 | Week 16 IGA improvement. >=2 n=24,13,11 | Week 16 IGA 0/1 n=24,13,11 | Week 20 IGA <=2 n=24,0,11 | Week 20 IGA improvement. >=2 n=24,0,11 | Week 20 IGA 0/1 n=24,0,11 | Week 24 IGA <=2 n=24,0,10 | Week 24 IGA improvement. >=2 n=24,0,10 | Week 24 IGA 0/1 n=24,0,10 | Week 28 IGA <=2 n=23,0,11 | Week 28 IGA improvement. >=2 n=23,0,11 | Week 28 IGA 0/1 n=23,0,11 | Week 32 IGA <=2 n=23,0,10 | Week 32 IGA improvement. >=2 n=23,0,10 | Week 32 IGA 0/1 n=23,0,10 | |
| Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 1 | 1 | 0 | 3 | 2 | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 1 | 0 |
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 IGA <=2 n=24,12,0 | Week 2 IGA improvement >=2 n=24,12,0 | Week 2 IGA 0/1 n=24,12,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,11 | Week 16 IGA improvement. >=2 n=24,13,11 | Week 16 IGA 0/1 n=24,13,11 | Week 20 IGA <=2 n=24,0,11 | Week 20 IGA improvement. >=2 n=24,0,11 | Week 20 IGA 0/1 n=24,0,11 | Week 24 IGA <=2 n=24,0,10 | Week 24 IGA improvement. >=2 n=24,0,10 | Week 24 IGA 0/1 n=24,0,10 | Week 28 IGA <=2 n=23,0,11 | Week 28 IGA improvement. >=2 n=23,0,11 | Week 28 IGA 0/1 n=23,0,11 | Week 32 IGA <=2 n=23,0,10 | Week 32 IGA improvement. >=2 n=23,0,10 | Week 32 IGA 0/1 n=23,0,10 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 5 | 1 | 1 | 4 | 1 | 1 | 5 | 0 | 0 | 5 | 5 | 4 | 9 | 5 | 4 | 10 | 5 | 5 | 10 | 3 | 3 | 7 | 1 | 1 | 9 | 2 | 2 |
The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline n=24,13,13 | Week 16 n=24,13,13 | |
| Placebo - TP 1 - LPP Cohort | 5.95 | -2.24 |
The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline n=24,13,13 | Week 16 n=24,13,13 | Week 32 n=24,0,13 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 5.92 | -1.44 | -2.44 |
| Placebo to AIN457 300 mg Q2W TP 2 - Lpp Cohort | 5.95 | -2.24 | -3.20 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline - Question 1 | Week 16 Severity of itch during past 24 hours n=25,12,10 | Baseline- Question 2 | Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10 | Baseline- Question 3 | Week 16 How bothered by Itch during past 24 hours n=25,12,10 | |
| Placebo - TP 1 - CLP Cohort | 5.7 | -2.3 | 6.3 | -2.7 | 6.1 | -2.7 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline - Question 1 | Week 16 Severity of itch during past 24 hours n=25,12,10 | Week 32 Severity of itch during past 24 hours n=25,0,9 | Baseline- Question 2 | Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10 | Week 32 How severe was itch at worst moment during past 24 hours n=25,0,9 | Baseline- Question 3 | Week 16 How bothered by Itch during past 24 hours n=25,12,10 | Week 32 How bothered by Itch during past 24 hours n=25,0,9 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 5.1 | -0.8 | -1.5 | 5.6 | -0.9 | -1.3 | 4.8 | -1.0 | -1.1 |
| Placebo to AIN457 300 mg Q2W TP 2 - CLP Cohort | 5.8 | -2.0 | -1.1 | 5.9 | -1.9 | -1.2 | 6.1 | -2.4 | -1.2 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline - Question 1 n=24,13,13 | Week 16 Severity of itch during past 24 hours n=24,13,11 | Baseline - Question 2 n=24,13,13 | Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=24,13,13 | |
| Placebo - TP 1 - LPP Cohort | 3.8 | -1.1 | 4.2 | -1.3 | 3.2 | -1.2 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline - Question 1 n=24,13,13 | Week 16 Severity of itch during past 24 hours n=24,13,11 | Week 32 Severity of itch during past 24 hours n=24,0,11 | Baseline - Question 2 n=24,13,13 | Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13 | Week 32 How severe was itch at worst moment during past 24 hours n=24,0,11 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=24,13,13 | Week 32 How bothered by Itch during past 24 hours n=24,0,11 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 4.5 | -0.5 | -1.6 | 5.1 | -0.7 | -1.8 | 4.0 | -0.4 | -1.7 |
| Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort | 3.8 | -1.1 | -2.4 | 4.1 | -1.3 | -2.6 | 3.2 | -1.2 | -2.2 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline - Question 1 n=23,13,11 | Week 16 Severity of itch during past 24 hours n=23,13,11 | Baseline - Question 2 n=23,13,11 | Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=23,13,11 | |
| Placebo - TP 1 - MLP Cohort | 3.8 | -0.2 | 3.6 | 0.4 | 4.0 | 0.1 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline - Question 1 n=23,13,11 | Week 16 Severity of itch during past 24 hours n=23,13,11 | Week 32 Severity of itch during past 24 hours n=22,0,10 | Baseline - Question 2 n=23,13,11 | Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11 | Week 32 How severe was itch at worst moment during past 24 hours n=22,0,10 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=23,13,11 | Week 32 How bothered by Itch during past 24 hours n=22,0,10 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 2.5 | 0.3 | 0.1 | 2.4 | 0.8 | 0.3 | 3.4 | -0.5 | -0.2 |
| Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 4.3 | -0.3 | -0.4 | 4.1 | 0.4 | 0.4 | 4.5 | 0.0 | -0.4 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline - Question 1 n=25,12,10 | Week 16 Severity of pain during past 24 hours n=25,12,10 | Baseline - Question 2 n=25,12,10 | Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10 | Baseline - Question 3 n=25,12,10 | Week 16 How bothered by pain during past 24 hour n=25,12,10 | |
| Placebo - TP 1 - CLP Cohort | 3.4 | -0.8 | 3.9 | -1.2 | 3.7 | -0.6 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline - Question 1 n=25,12,10 | Week 16 Severity of pain during past 24 hours n=25,12,10 | Week 32 Severity of pain during past 24 hours n=25,0,9 | Baseline - Question 2 n=25,12,10 | Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10 | Week 32 How severe was pain at worst moment during past 24 hours n=25,0,9 | Baseline - Question 3 n=25,12,10 | Week 16 How bothered by pain during past 24 hour n=25,12,10 | Week 32 How bothered by pain during past 24 hours n=25, 0,9 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 1.09 | 0.2 | -0.3 | 2.2 | 0.1 | -0.4 | 2.1 | 0.1 | -0.2 |
| Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 3.5 | -0.8 | -0.3 | 3.9 | -1.0 | -0.4 | 3.8 | 0.5 | -0.3 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline - Question 1 n=24,13,12 | Week 16 Severity of pain during past 24 hours n=24,13,12 | Baseline - Question 2 24,13,12 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12 | Baseline - Question 3 n=24,13,12 | Week 16 How bothered by pain during past 24 hour n=24,13,12 | |
| Placebo - TP 1 - LPP Cohort | 2.0 | -0.5 | 2.5 | -0.9 | 2.4 | -1.1 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline - Question 1 n=24,13,12 | Week 16 Severity of pain during past 24 hours n=24,13,12 | Week 32 Severity of pain during past 24 hours n=24,0,11 | Baseline - Question 2 24,13,12 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12 | Week 32 How severe was pain at worst moment during past 24 hours n=24,0,11 | Baseline - Question 3 n=24,13,12 | Week 16 How bothered by pain during past 24 hour n=24,13,12 | Week 32 How bothered by pain during past 24 hours n=24,0,11 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 2.5 | 0.3 | -0.6 | 2.8 | 0.2 | -0.8 | 2.7 | 0.0 | -0.8 |
| Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort | 2.0 | -0.5 | -1.5 | 2.5 | -0.9 | -2.0 | 2.4 | -1.1 | -1.9 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline - Question 1 n=24,13,11 | Week 16 Severity of pain during past 24 hours n=24,13,11 | Baseline - Question 2 n=24,13,11 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by pain during past 24 hour n=24,13,11 | |
| Placebo - TP 1 - MLP Cohort | 5.9 | -0.1 | 6.4 | -0.3 | 6.5 | -0.3 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline - Question 1 n=24,13,11 | Week 16 Severity of pain during past 24 hours n=24,13,11 | Week 32 Severity of pain during past 24 hours n=23,0,10 | Baseline - Question 2 n=24,13,11 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11 | Week 32 How severe was pain at worst moment during past 24 hours n=23,0,10 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by pain during past 24 hour n=24,13,11 | Week 32 How bothered by pain during past 24 hours n=23,0,10 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 5.1 | -0.5 | -0.3 | 5.4 | -0.5 | -0.3 | 5.5 | -0.8 | -0.5 |
| Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 6.3 | 0.0 | -0.6 | 6.7 | -0.2 | -0.5 | 6.8 | -0.1 | -0.9 |
Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline n=24,13,12 | Week 16 n=24,13,12 | |
| Placebo - TP 1 - LPP Cohort | 54.01 | -6.94 |
Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline n=24,13,12 | Week 16 n=24,13,12 | Week 32 n=24,0,11 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 -LPP Cohort | 55.75 | 1.86 | -4.26 |
| Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort | 54.01 | -6.94 | -14.43 |
OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline n=21,12,10 | Week 16 n=21,12,10 | |
| Placebo - TP 1 - MLP Cohort | 13.4 | 0.8 |
OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline n=21,12,10 | Week 16 n=21,12,10 | Week 32 n=20,0,9 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 11.0 | -1.0 | -1.8 |
| Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 13.9 | -0.4 | -0.7 |
REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline n=21,12,10 | Week 16 n=21,12,10 | |
| Placebo - TP 1 - MLP Cohort | 25.29 | -5.79 |
REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline n=21,12,10 | Week 16 n=21,12,10 | Week 32 n=20,0,9 | |
| AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 21.31 | -4.83 | -6.08 |
| Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 26.95 | -4.10 | -2.17 |
15 reviews available for salicylic acid and Lichen Planus
| Article | Year |
|---|---|
[Frontal fibrosing alopecia-update].
Topics: Adolescent; Alopecia; Eyebrows; Female; Fibrosis; Humans; Inflammation; Lichen Planus; Male; Scalp | 2022 |
Frontal Fibrosing Alopecia - a review and a practical guide for clinicians.
Topics: Alopecia; Child, Preschool; Female; Forehead; Humans; Hydroxychloroquine; Lichen Planus; Scalp | 2022 |
PPAR-γ signalling as a key mediator of human hair follicle physiology and pathology.
Topics: Alopecia; Animals; Cicatrix; Epithelial-Mesenchymal Transition; Hair; Hair Diseases; Hair Follicle; | 2020 |
Fibrosing alopecia in a pattern distribution.
Topics: Alopecia; Female; Fibrosis; Hair Follicle; Humans; Lichen Planus; Male; Middle Aged; Scalp | 2021 |
Hair Transplantation in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Systematic Review.
Topics: Alopecia; Dermoscopy; Hair; Humans; Lichen Planus; Scalp | 2021 |
Common causes of hair loss - clinical manifestations, trichoscopy and therapy.
Topics: Alopecia; Alopecia Areata; Hair Diseases; Humans; Lichen Planus; Scalp; Trichotillomania | 2021 |
Diagnostic Accuracy of Trichoscopy in Inflammatory Scalp Diseases: A Systematic Review.
Topics: Dermatitis, Contact; Dermatitis, Seborrheic; Dermoscopy; Humans; Lichen Planus; Lupus Erythematosus, | 2022 |
A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris.
Topics: Humans; Lichen Planus; Scalp; Scalp Dermatoses | 2021 |
[Postmenopausal lichen planopilaris also known as fibrosing frontotemporal alopecia Kossard : An evidence-oriented practical guide to treatment from the University of the Saarland, Hair Research Center of the Dr. Rolf M. Schwiete Foundation].
Topics: Adult; Aged; Algorithms; Alopecia; Diagnosis, Differential; Evidence-Based Medicine; Female; Fibrosi | 2018 |
A proposed mechanism for central centrifugal cicatricial alopecia.
Topics: Alopecia; Cicatrix; Fibrosis; Humans; Kidney; Kidney Diseases; Lichen Planus; PPAR gamma; Scalp; Scl | 2020 |
Pediatric ocular lichen planus and lichen planopilaris: One new case and a review of the literature.
Topics: Child; Cyclosporine; Eye; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lichen Planus; | 2018 |
Graham-Little-Piccardi-Lasseur syndrome: case report and review of the syndrome in men.
Topics: Abnormalities, Multiple; Adult; Alopecia; Axilla; Cicatrix; Darier Disease; Eyebrows; Humans; Lichen | 2014 |
Primary scarring alopecias.
Topics: Acne Keloid; Alopecia; Cellulitis; Cicatrix; Fibrosis; Folliculitis; Humans; Lichen Planus; Lupus Er | 2015 |
Dermatitis herpetiformis associated with lichen planopilaris.
Topics: Autoimmune Diseases; Biopsy; Chronic Disease; Dermatitis Herpetiformis; Humans; Lichen Planus; Male; | 1995 |
[Hair casts in lichen ruber].
Topics: Antifungal Agents; Diagnosis, Differential; Drug Therapy, Combination; Hair; Humans; Lichen Planus; | 1993 |
80 other studies available for salicylic acid and Lichen Planus
| Article | Year |
|---|---|
Lichen planus-like drug eruption due to para-amino salicylic acid; report of 5 cases, two showing mouth lesions.
Topics: Aminosalicylic Acid; Drug Eruptions; Humans; Lichen Planus; Mouth; Mouth Diseases; Salicylic Acid; T | 1953 |
Plasma Cell-Predominant Lichen Planopilaris.
Topics: Alopecia; Hair Follicle; Humans; Lichen Planus; Male; Middle Aged; Plasma Cells; Scalp | 2022 |
The presence of mast cells in lichen planopilaris and discoid lupus erythematosus of the scalp: A quantitative study.
Topics: Alopecia; Cell Count; Humans; Lichen Planus; Lupus Erythematosus, Discoid; Mast Cells; Scalp | 2022 |
Scalp reduction surgery does not reactivate frontal fibrosing alopecia: A case report.
Topics: Alopecia; Humans; Lichen Planus; Plastic Surgery Procedures; Scalp | 2022 |
A prospective pilot study of narrowband UV-B treatment of lichen planopilaris.
Topics: Alopecia; Humans; Lichen Planus; Pilot Projects; Prospective Studies; Scalp | 2022 |
Inflammatory complications after hair transplantation: Report of 10 cases.
Topics: Alopecia; Eczema; Female; Hair; Humans; Lichen Planus; Male; Scalp | 2022 |
IL-17 Expression in the Perifollicular Fibrosis in Biopsies From Lichen Planopilaris.
Topics: Alopecia; Biopsy; Cicatrix; Fibrosis; Humans; Interleukin-17; Lichen Planus; Retrospective Studies; | 2022 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States | 2023 |
Protein profiling of forehead epidermal corneocytes distinguishes frontal fibrosing from androgenetic alopecia.
Topics: Alopecia; Epidermis; Fibrosis; Forehead; Humans; Lichen Planus; Scalp; Skin | 2023 |
Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series.
Topics: Alopecia; Alopecia Areata; Cicatrix; Humans; Lichen Planus; Sarcoidosis; Scalp | 2023 |
A Case of Secondary Osteoma Cutis Associated with Lichen Planopilaris.
Topics: Alopecia; Bone Diseases, Metabolic; Clobetasol; Female; Glucocorticoids; Humans; Hydroxychloroquine; | 2019 |
Profiling the human hair follicle immune system in lichen planopilaris and frontal fibrosing alopecia: can macrophage polarization differentiate these two conditions microscopically?
Topics: Alopecia; Hair Follicle; Humans; Lichen Planus; Macrophages; Scalp | 2020 |
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing.
Topics: Alopecia; Alopecia Areata; Humans; Janus Kinase 3; Lichen Planus; Quality of Life; Scalp | 2020 |
Eosinophilic folliculitis of the scalp associated with PD-1/PDL1 inhibitors.
Topics: Alopecia; Folliculitis; Humans; Immune Checkpoint Inhibitors; Lichen Planus; Programmed Cell Death 1 | 2020 |
Report of two cases of mucous membrane pemphigoid with frontal fibrosing alopecia: a variant of lichen planus pemphigoides or an incidental finding?
Topics: Aged; Alopecia; Female; Gingivitis; Humans; Lichen Planus; Mouth Diseases; Mouth Mucosa; Pemphigoid, | 2020 |
Cicatricial pattern hair loss is not a variant of lichen planopilaris.
Topics: Alopecia; Humans; Lichen Planus; Scalp | 2020 |
Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab.
Topics: Alopecia; Antibodies, Monoclonal, Humanized; Cicatrix; Fibrosis; Humans; Lichen Planus; Scalp | 2020 |
Features of classic lichen planopilaris and frontal fibrosing alopecia in reflectance confocal microscopy: A preliminary study.
Topics: Alopecia; Hair Follicle; Humans; Lichen Planus; Microscopy, Confocal; Scalp | 2021 |
Lichen planopilaris in men: a retrospective clinicopathologic study of 19 patients.
Topics: Alopecia; Clobetasol; Female; Humans; Lichen Planus; Male; Retrospective Studies; Scalp | 2021 |
Co-localization of alopecia areata and lichen planopilaris in a patient receiving immunosuppressants: A rare case.
Topics: Adult; Alopecia; Alopecia Areata; Female; Hair Follicle; Humans; Immunosuppressive Agents; Lichen Pl | 2021 |
Colour Doppler ultrasound study in patients with frontal fibrosing alopecia.
Topics: Alopecia; Cross-Sectional Studies; Female; Fibrosis; Humans; Lichen Planus; Scalp; Ultrasonography, | 2021 |
Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement.
Topics: Alopecia; Alopecia Areata; Biomarkers; Cross-Sectional Studies; Female; Fibrosis; Humans; Lichen Pla | 2022 |
Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG).
Topics: Alopecia; Cicatrix; Clinical Trials as Topic; Consensus; Guidelines as Topic; Humans; Lichen Planus; | 2021 |
Scalp demodicosis developing in a patient with frontal fibrosing alopecia: a clinical and trichoscopic mimicker of active disease.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Scalp | 2022 |
Flushing episodes in the context of frontal fibrosing alopecia with facial papules.
Topics: Alopecia; Female; Forehead; Humans; Lichen Planus; Retrospective Studies; Scalp | 2021 |
Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study.
Topics: Alopecia; Alopecia Areata; Female; Humans; Lichen Planus; Middle Aged; Retrospective Studies; Scalp; | 2021 |
Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases.
Topics: Adult; Aged; Alopecia; Anti-Inflammatory Agents; Cheek; Cicatrix; Clobetasol; Dermatologic Agents; E | 2017 |
Hair transplantation for the treatment of lichen planopilaris and frontal fibrosing alopecia: A report of two cases.
Topics: Adult; Alopecia; Female; Fibrosis; Forehead; Hair; Humans; Lichen Planus; Middle Aged; Scalp | 2018 |
Cicatricial Alopecia Research Foundation meeting, May 2016: Progress towards the diagnosis, treatment and cure of primary cicatricial alopecias.
Topics: Alopecia; Animals; Cicatrix; Disease Models, Animal; Dogs; Fibrosis; Humans; Lichen Planus; Mice; Sc | 2018 |
The timing and distribution of nonscalp hair loss in patients with lichen planopilaris and frontal fibrosing alopecia: A survey-based study.
Topics: Alopecia; Female; Fibrosis; Humans; Lichen Planus; Middle Aged; Scalp; Self Report; Time Factors | 2021 |
Lichen planopilaris beyond scalp: a case series with dermoscopy-histopathology correlation.
Topics: Adult; Dermoscopy; Female; Humans; Lichen Planus; Male; Middle Aged; Scalp; Scalp Dermatoses | 2018 |
Scalp porocarcinoma and lichen planopilaris.
Topics: Adult; Eccrine Porocarcinoma; Female; Hair Follicle; Head and Neck Neoplasms; HIV Infections; Humans | 2018 |
Tofacitinib for the treatment of lichen planopilaris: A case series.
Topics: Administration, Oral; Adult; Aged; Alopecia; Dermatologic Agents; Drug Administration Schedule; Fema | 2018 |
"Normal-appearing" scalp areas are also affected in lichen planopilaris and frontal fibrosing alopecia: An observational histopathologic study of 40 patients.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Biopsy; Dermatology; Female; Fibrosis; Humans; Inflammatio | 2020 |
Evidence for neurogenic inflammation in lichen planopilaris and frontal fibrosing alopecia pathogenic mechanism.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Biopsy; Calcitonin Gene-Related Peptide; Chronic Disease; | 2020 |
Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia Mimicking Discoid Lupus Erythematosus.
Topics: Aged; Alopecia; Diagnosis, Differential; Female; Fibrosis; Humans; Lichen Planus; Lupus Erythematosu | 2019 |
Oral lichen planus and lichen planopilaris complicated with thymoma.
Topics: Aged; Alopecia; Biopsy; Cobalt; Female; Hair Follicle; Humans; Lichen Planus; Lichen Planus, Oral; M | 2019 |
Frontal fibrosing alopecia: A new autoimmune entity?
Topics: Adult; Aged; Alopecia; Animals; Autoimmune Diseases; Cicatrix; Female; Fibrosis; Humans; Lichen Plan | 2019 |
Dermoscopic features of lichen planopilaris in Northern Iran: a prospective observational study.
Topics: Adult; Alopecia; Biopsy; Cicatrix; Dermoscopy; Feasibility Studies; Female; Hair; Hair Diseases; Hum | 2019 |
Isolated linear lichen planopilaris: extremely rare when limited to the scalp.
Topics: Adult; Cicatrix; Follow-Up Studies; Forehead; Humans; Lichen Planus; Male; Scalp | 2013 |
Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome.
Topics: Alopecia; Aminoquinolines; Antineoplastic Agents; Basal Cell Nevus Syndrome; Drug Eruptions; Female; | 2015 |
Absence of HLA-DR1 positivity in 2 familial cases of frontal fibrosing alopecia.
Topics: Alopecia; Antibodies; Female; Fibrosis; HLA-DR1 Antigen; Humans; Lichen Planus; Middle Aged; Scalp; | 2014 |
Lichen planopilaris with foreign-body granuloma.
Topics: Alopecia; Biopsy; Fibrosis; Granuloma, Foreign-Body; Hair Follicle; Humans; Lichen Planus; Male; Mid | 2015 |
A case of Graham-Little-Piccardi-Lasseur syndrome.
Topics: Aged; Alopecia; Axilla; Female; Groin; Humans; Lichen Planus; Scalp; Syndrome | 2015 |
Violaceous Eruption on the Head and Extremities. Lichen Planus Actinicus.
Topics: Biopsy; Extremities; Humans; Lichen Planus; Male; Middle Aged; Scalp | 2015 |
The Use of Anti-Keratin 903 Antibodies to Visualize Colloid Bodies and Diagnose Lichen Planopilaris.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies; Antibodies, Monoclonal, Murine-Derived; Biomar | 2016 |
Reflectance confocal microscopy for scarring and non-scarring alopecia real-time assessment.
Topics: Alopecia Areata; Biopsy; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Humans; Lichen Planu | 2016 |
Frontal fibrosing alopecia: a disease fascinating for the researcher, disappointing for the clinician and distressing for the patient.
Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Scalp | 2016 |
Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus.
Topics: Aged; Erythema; Female; Humans; Immunosuppressive Agents; Lichen Planus; Lichen Planus, Oral; Middle | 2016 |
A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia.
Topics: Adult; Aged; Alopecia; Biopsy; Cross-Sectional Studies; Diagnosis, Differential; Female; Hair Follic | 2016 |
Frontal fibrosing alopecia.
Topics: Aged; Alopecia; Female; Fibrosis; Hair Preparations; Humans; Laser Therapy; Lichen Planus; Male; Sca | 2017 |
A histologic review of 27 patients with lichen planopilaris.
Topics: Adult; Aged; Alopecia; Biopsy; Cicatrix; Female; Humans; Lichen Planus; Male; Middle Aged; Retrospec | 2008 |
Frontal fibrosing alopecia: clinical presentations and prognosis.
Topics: Adult; Aged; Alopecia; Cicatrix; Disease Progression; Eyebrows; Female; Fibrosis; Forehead; Hair Fol | 2009 |
Lichen planopilaris and pseudopelade of Brocq involve distinct disease associated gene expression patterns by microarray.
Topics: Alopecia; Animals; Biopsy; Cluster Analysis; False Positive Reactions; Gene Expression; Gene Express | 2010 |
Generalized reticulated hyperpigmentation induced by lichen planus.
Topics: Aged; Diagnosis, Differential; Female; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation; | 2009 |
Type 1 interferon signature in the scalp lesions of alopecia areata.
Topics: Alopecia Areata; Hair Follicle; Humans; Interferon Type I; Lichen Planus; Lupus Erythematosus, Disco | 2010 |
Frontal fibrosing alopecia associated with generalized hair loss.
Topics: Aged; Alopecia; Eyebrows; Female; Fibrosis; Hair; Humans; Lichen Planus; Middle Aged; Postmenopause; | 2010 |
Expanding the spectrum of frontal fibrosing alopecia: a unifying concept.
Topics: Adult; Age Distribution; Aged; Alopecia; Biopsy, Needle; Cohort Studies; Diagnosis, Differential; Di | 2010 |
The follicular triad: a pathological clue to the diagnosis of early frontal fibrosing alopecia.
Topics: Alopecia; Early Diagnosis; Fibrosis; Forehead; Humans; Lichen Planus; Middle Aged; Scalp | 2012 |
Erosive lichen planus of the scalp and hepatitis C infection.
Topics: Alopecia; Biopsy; Glucocorticoids; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Lichen | 2013 |
Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University.
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Anti-Bacterial Agents; Azasteroids; Cicatrix; D | 2013 |
[Kossard frontal fibrosing alopecia in a man].
Topics: Aged; Alopecia; Biopsy; Fibrosis; Hair Follicle; Humans; Lichen Planus; Male; Scalp; Sex Factors | 2002 |
Nodular neurodermatitis of the scalp.
Topics: Head; Humans; Lichen Planus; Neurodermatitis; Scalp | 1951 |
[Histopathology of lichen ruber planus on the scalp].
Topics: Disease; Head; Humans; Lichen Planus; Scalp | 1955 |
[Pseudopelade; statistics of 109 new cases; findings on lichen planus of the scalp].
Topics: Alopecia; Biometry; Humans; Lichen Planus; Scalp | 1957 |
[Lichen sclerosus et atrophicus of the scalp and other localizations].
Topics: Disease; Humans; Lichen Planus; Lichen Sclerosus et Atrophicus; Medical Records; Scalp; Skin Disease | 1961 |
[Lichen of the scalp].
Topics: Disease; Exanthema; Humans; Lichen Planus; Lichens; Scalp; Skin Diseases | 1961 |
Frontal fibrosing alopecia versus lichen planopilaris: a clinicopathological study.
Topics: Aged; Aged, 80 and over; Alopecia; Apoptosis; Biopsy; Female; Fibrosis; Fluorescent Antibody Techniq | 2006 |
Subtle clues to diagnosis by immunopathology. Scarring alopecia.
Topics: Alopecia; Fluorescent Antibody Technique; Humans; Lichen Planus; Lupus Erythematosus, Systemic; Scal | 1980 |
Pseudopelade of Brocq is lichen planopilaris: report of four cases that support this nosology.
Topics: Adult; Aged; Alopecia Areata; Female; Humans; Lichen Planus; Male; Middle Aged; Scalp; Scalp Dermato | 1993 |
A clinicopathological study of scarring alopecia.
Topics: Adult; Alopecia; Child; Child, Preschool; Female; Fibrin; Fluorescent Antibody Technique; Humans; Li | 1993 |
Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Antimalarials; Biopsy; Chloroquine; Dermato | 1997 |
[Lichen planopilaris simulating postmenopausal frontal fibrosing alopecia (Kossard)].
Topics: Aged; Alopecia; Diagnosis, Differential; Female; Fibrosis; Hair Follicle; Humans; Lichen Planus; Mid | 1998 |
Lichen planopilaris-like changes arising within an epidermal nevus: does this case suggest clues to the etiology of lichen planopilaris?
Topics: Adolescent; Alopecia; Humans; Lichen Planus; Male; Nevus, Intradermal; Scalp; Skin Neoplasms | 2000 |
[Discoid lupus erythematosus or lichen planus?].
Topics: Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lichen Planus; Lupus Eryth | 1978 |
Lichen planopilaris: a clinicopathologic study.
Topics: Adult; Aged; Epidermis; Epithelium; Female; Fibrosis; Humans; Hyperplasia; Lichen Planus; Male; Midd | 1990 |
[The Brocq pseudopelade--a disease picture or disease entity].
Topics: Adolescent; Adult; Aged; Alopecia; Child; Child, Preschool; Cicatrix; Diagnosis, Differential; Femal | 1989 |
[Scientific session of the Munich Dermatological society Inc. and the Association of Gerfman Residential Dermatologist, Munich branch, on November 29, 1967].
Topics: Abscess; Acanthosis Nigricans; Adult; Aged; Anus Diseases; Axilla; Carcinoma, Basal Cell; Child; Con | 1968 |
[Lichen planus with onychatrophy and cicatricial alopecia (author's transl)].
Topics: Alopecia; Atrophy; Biopsy; Blister; Cicatrix; Female; Foot Dermatoses; Hallux; Humans; Lichen Planus | 1973 |
[On the effect of the age and factors of the environment upon lichen pilaris and xeroderma].
Topics: Aging; Environment; Humans; Ichthyosis; Lichen Planus; Scalp | 1965 |